PL1828378T3 - Deacylacja lps w bakteriach gram ujemnych - Google Patents

Deacylacja lps w bakteriach gram ujemnych

Info

Publication number
PL1828378T3
PL1828378T3 PL05815467T PL05815467T PL1828378T3 PL 1828378 T3 PL1828378 T3 PL 1828378T3 PL 05815467 T PL05815467 T PL 05815467T PL 05815467 T PL05815467 T PL 05815467T PL 1828378 T3 PL1828378 T3 PL 1828378T3
Authority
PL
Poland
Prior art keywords
deacylation
lps
negative bacteria
gram negative
gram
Prior art date
Application number
PL05815467T
Other languages
English (en)
Polish (pl)
Inventor
Johannes Petrus Maria Tommassen
Der Ley Peter André Van
Jeroen Johannes Gerardus Geurtsen
Original Assignee
De Staat Der Nederlanden Vert Door De Mini Van Vws Mini Van Volksgezondheid Welzijn En Sport
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Staat Der Nederlanden Vert Door De Mini Van Vws Mini Van Volksgezondheid Welzijn En Sport filed Critical De Staat Der Nederlanden Vert Door De Mini Van Vws Mini Van Volksgezondheid Welzijn En Sport
Publication of PL1828378T3 publication Critical patent/PL1828378T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05815467T 2004-12-17 2005-12-16 Deacylacja lps w bakteriach gram ujemnych PL1828378T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078445 2004-12-17
EP05815467.5A EP1828378B1 (en) 2004-12-17 2005-12-16 Deacylation of lps in gram negative bacteria
PCT/NL2005/050081 WO2006065139A2 (en) 2004-12-17 2005-12-16 Deacylation of lps in gram negative bacteria

Publications (1)

Publication Number Publication Date
PL1828378T3 true PL1828378T3 (pl) 2014-10-31

Family

ID=34928754

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05815467T PL1828378T3 (pl) 2004-12-17 2005-12-16 Deacylacja lps w bakteriach gram ujemnych

Country Status (15)

Country Link
US (1) US8048433B2 (enExample)
EP (1) EP1828378B1 (enExample)
JP (1) JP5378685B2 (enExample)
CN (1) CN101203605B (enExample)
AU (1) AU2005317304B2 (enExample)
BR (1) BRPI0519923A8 (enExample)
CA (1) CA2590906C (enExample)
DK (1) DK1828378T3 (enExample)
ES (1) ES2493440T3 (enExample)
MX (1) MX2007007288A (enExample)
NO (1) NO340331B1 (enExample)
NZ (1) NZ555889A (enExample)
PL (1) PL1828378T3 (enExample)
PT (1) PT1828378E (enExample)
WO (1) WO2006065139A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2134743E (pt) * 2007-03-26 2012-12-21 Nederlanden Staat Vacinas melhoradas contra bordotella pertussis baseadas nos mutantes do lps glicosiltransferase
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EA031879B1 (ru) 2013-06-04 2019-03-29 Пётр Геннадиевич Апарин Модифицированный липополисахарид эндотоксичных бактерий (варианты), комбинация модифицированных липополисахаридов (варианты) и включающие их вакцина (варианты) и фармацевтическая композиция (варианты)
US11052142B2 (en) 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US20160193322A1 (en) 2013-08-05 2016-07-07 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
CN104388368B (zh) * 2014-10-30 2017-02-15 四川农业大学 一株低内毒素大肠杆菌原核表达工程菌突变株及构建方法
WO2017129752A1 (en) * 2016-01-28 2017-08-03 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Modified tetra-acylated neisserial lps
CN105567620B (zh) * 2016-01-29 2019-03-19 江南大学 一株产减毒类脂A的Cronobacter sakazakii突变株及其应用
CN105695540A (zh) * 2016-03-18 2016-06-22 辽宁成大生物股份有限公司 一种革兰氏阴性菌胞壁抗原的制备方法
CN110461865A (zh) * 2017-03-13 2019-11-15 由卫生福利和体育大臣代表的荷兰王国 包含具有降低的反应原性的lps的博德特氏菌疫苗
WO2018213242A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
KR102822764B1 (ko) * 2017-12-04 2025-06-19 인트라백 비.브이. 외막 소포의 생성을 위한 개선된 방법
US20230183656A1 (en) * 2020-05-14 2023-06-15 Merck Patent Gmbh Methods and compositions for purifying adeno associated virus particles or adenoviruses
WO2022049222A1 (en) 2020-09-04 2022-03-10 Intravacc B.V. Ompa mutations enhance omv production in bordetella pertussis
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH650681A5 (en) * 1981-08-14 1985-08-15 Dso Pharmachim Whooping cough vaccine
JP2918895B2 (ja) * 1987-09-04 1999-07-12 アムジエン・インコーポレーテツド 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
ATE263244T1 (de) * 1992-08-18 2004-04-15 Dimminaco Ag Bordetella bronchiseptica impfstoff
CA2220048C (en) * 1995-05-04 2006-03-07 Connaught Laboratories Limited Acellular pertussis vaccines and methods of preparation thereof
US6887483B2 (en) 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
ATE278419T1 (de) * 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6482807B1 (en) * 1998-11-03 2002-11-19 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US20030113742A1 (en) * 2001-04-20 2003-06-19 University Of Iowa Research Foundation Methods and compositions for the modulation of biofilm formation

Also Published As

Publication number Publication date
JP5378685B2 (ja) 2013-12-25
NO340331B1 (no) 2017-04-03
NO20073088L (no) 2007-09-17
BRPI0519923A2 (pt) 2009-08-11
WO2006065139A3 (en) 2006-10-19
US8048433B2 (en) 2011-11-01
DK1828378T3 (da) 2014-09-01
JP2008523805A (ja) 2008-07-10
EP1828378B1 (en) 2014-06-11
CN101203605B (zh) 2016-01-27
CA2590906A1 (en) 2006-06-22
NZ555889A (en) 2009-07-31
MX2007007288A (es) 2008-02-25
ES2493440T3 (es) 2014-09-11
BRPI0519923A8 (pt) 2018-01-23
AU2005317304B2 (en) 2011-06-23
PT1828378E (pt) 2014-10-10
CN101203605A (zh) 2008-06-18
EP1828378A2 (en) 2007-09-05
AU2005317304A1 (en) 2006-06-22
CA2590906C (en) 2017-01-03
US20080274145A1 (en) 2008-11-06
WO2006065139A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
PL1828378T3 (pl) Deacylacja lps w bakteriach gram ujemnych
GB0422052D0 (en) Enzymes
IL191057A0 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
GB0307026D0 (en) Bacterial supplement
IL172988A0 (en) Bioreactor
GB0410118D0 (en) Novel bioreactor
GB0604973D0 (en) Purification method and kit
GB0511602D0 (en) Microorganisms
EP1848798A4 (en) NEW MICROBIAL ENZYMES AND THEIR USE
GB0410958D0 (en) Methods for reducing biofilm formation in infectious bacteria
GB0420881D0 (en) Bioreactor
EP1800663A4 (en) ENTERALER FOOD
GB0426182D0 (en) Photoporation of cells
ZA200610279B (en) Treatment of bacterial infections
GB0326062D0 (en) Bioreactor
HK1103749A (en) Methods for reducing biofilm formation in infectious bacteria
HU0401841D0 (en) Combined micropropagating process and bioreactor
HK1121457A (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
GB0403452D0 (en) Desaturase enzymes
GB0522696D0 (en) Balustrading kit and method
GB0419204D0 (en) Bacteria
GB0319436D0 (en) Improvements in enzymes
AU2004907245A0 (en) Bacterial treatment
AU2004900839A0 (en) Bacterial treatment
GB0315183D0 (en) Bioreactor